Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04847596 · ClinicalTrials.gov registry record
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 25
- Enrollment target
NCT04847596 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT04847596 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a scheduled second dose, or already completed full course (two dose) vaccination. Fully vaccinated participants must be able to complete immune assay No.1 ≥ 14 days after the second dose of vaccine
Interventions
- OTHER Ofatumumab
- OTHER Covid-19 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2022-02-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04847596
The ClinicalTrials.gov registry entry for NCT04847596 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ofatumumab is the first listed.
NCT04847596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04847596 about?
NCT04847596 is a clinical study titled "A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab". This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a scheduled second dose, or already completed full course (two dose) vaccinat...
What is the current status of trial NCT04847596?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2021-05-21. Estimated completion is 2022-02-18.
What interventions are being tested in trial NCT04847596?
The interventions under investigation include: Ofatumumab (OTHER), Covid-19 vaccine (OTHER).
Who is sponsoring clinical trial NCT04847596?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.